Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Kathryn E Flynn, PhD, Kevin P. Weinfurt, PhD, Li Lin, MS, Jerald P. Radich, MD, Charles A. Schiffer, MD, Michael J. Mauro, MD, Javier Pinilla Ibarz, MD PhD, Joseph O. Moore, MD, Richard A. Larson, MD, Vivian G. Oehler, MD, Michael W. Deininger, James E. Thompson, MD, Neil P Shah, MD PhD, Martha Wadleigh, MD, Ellen K. Ritchie, MD, Richard T. Silver, MD, Jorge E. Cortes, MD, Vamsi Kota, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 705.

https://doi.org/10.1182/blood-2019-126002

Published: 2019

Journal Articles

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Bjørn T. Gjertsen, MD PhD, Andreas Hochhaus, MD, Gianantonio Rosti, MD, Justin M. Watts, MD, Guillermo Ortí, Philipp le Coutre, MD, Eric Leip, PhD, Andrea Viqueira, MD, Jorge E. Cortes, MD, Frank Giles, MD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1639.

https://doi.org/10.1182/blood-2019-121815

Published: 2019

Journal Articles

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Chadi Nabhan, MDMBA, FACP, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 4057.

https://doi.org/10.1182/blood-2019-129632

Published: 2019

Journal Articles

Real-World Effectiveness and Safety of Eltrombopag in Patients with Aplastic Anemia: A Chinese Nationwide Survey

Wenrui Yang, MD, Bing Han, MD PhD, Hong Chang, MD, Bingyi Wu, MD, Fankai Meng, Dexiang Ji, MD, Yingmei Li, MD, Zhengjin Zheng, MD, Yan Fei, Jianping Shen, MD, Ping Hu, MD, Jianxiang Wang, MD, Fengkui Zhang, MD

Blood (2019) 134 (Supplement_1): 5020.

https://doi.org/10.1182/blood-2019-126441

Published: 2019

Journal Articles

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Anna Kalff, MBBS, Jake Shortt, MBBS FRACP FRCPA PhD, Flora Yuen, BBiomedSc, John Reynolds, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Craig Thomas Wallington-Beddoe, BSc,MBBS,PhDFRACP,FRCPA, Patricia Walker, MBBS, BMedSci, FRACP, FRCPA, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Rosanne Dunn, PhD, Andrew Spencer, DM

Blood (2019) 134 (Supplement_1): 3144.

https://doi.org/10.1182/blood-2019-130084

Published: 2019

Journal Articles

Impact of Early Switching to Nilotinib As Second Line TKI in Patients with Chronic Myeloid Leukemia Who Were Intolerant to, Suboptimal to and Failed Imatinib: The Thai Multi-Centered Study

Pongtep Viboonjuntra, MD, PhD, Arnuparp Lekhakula, MD, M.S., Kanchana Chansung, MD, Chittima Sirijerachai, MD, Pimjai Niparuck, MD, Teeraya Pauvilai, MD, Tontanai Numbenjapon, MD, Udomsak Bunworasate, MD, Weerasak Nawarawong, MD, Adisak Tantiworawit, MD, Tawatchai Suwanban, MD, Saengsuree Jootar, MD

Blood (2018) 132 (Supplement 1): 4267.

https://doi.org/10.1182/blood-2018-99-117787

Published: 2018

Journal Articles

Erythrocyte Deformability As a Potential Biomarker for Chronic Fatigue Syndrome

Amit K Saha, Brendan R Schmidt, BS, Julie Wilhelmy, BA, Vy Nguyen, Justin Do, Vineeth C Suja, MS, Mohsen Nemat-Gorgani, PhD, Anand K Ramasubramanian, PhD, Ronald W Davis, PhD

Blood (2018) 132 (Supplement 1): 4874.

https://doi.org/10.1182/blood-2018-99-117260

Published: 2018

Journal Articles

Relationship between Non-Prescribed Drug Use and Employment Status of Patients with Sickle Cell Disease

Modupe Idowu, MD, Tong Han Chung, PhD, Katherine Yu

Blood (2018) 132 (Supplement 1): 4932.

https://doi.org/10.1182/blood-2018-99-120373

Published: 2018

Journal Articles

Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort

Blood (2017) 130 (Supplement 1): 898.

https://doi.org/10.1182/blood.V130.Suppl_1.898.898

Published: 2017

Journal Articles

Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis

Ahmad Ghorab, MDMSc, Hagop M. Kantarjian, MD, Hesham Elhalawani, MD MS, Hoda Ahmed, MD MS, Ahmed Essam, MD, Omar Abdel-Rahman, MD PhD, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 2869.

https://doi.org/10.1182/blood.V130.Suppl_1.2869.2869

Published: 2017

Journal Articles

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Giuseppe Saglio, MD PhD, Timothy P. Hughes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Francis J. Giles, MD MB, FRCPath, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Prashanth Gopalakrishna, MD, Weiping Deng, Rafik Fellague-Chebra, MD, Sandip Acharya, MSc, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 1598.

https://doi.org/10.1182/blood.V130.Suppl_1.1598.1598

Published: 2017

Journal Articles

Variables Associated with Patient-Reported Symptoms in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors

Lu Yu, MD, Qian Jiang, MD

Blood (2017) 130 (Supplement 1): 1605.

https://doi.org/10.1182/blood.V130.Suppl_1.1605.1605

Published: 2017

Journal Articles

Pilot Study of Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia with Deep Molecular Response (EDI-PIO) — Evaluation of Pioglitazone in Treatment-Free Remission

Katia B Pagnano, MD, Eliana C Miranda, Marcia Torresan Delamain, Gislaine Oliveira Duarte, MD, Bruna Virgilio, Jessica Vianna, Erich Vinicius De Paula, MD PhD, Carmino Antonio De Souza, MD PhD

Blood (2017) 130 (Supplement 1): 1595.

https://doi.org/10.1182/blood.V130.Suppl_1.1595.1595

Published: 2017

Journal Articles

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Blood (2017) 130 (Supplement 1): 317.

https://doi.org/10.1182/blood.V130.Suppl_1.317.317

Published: 2017

Journal Articles

Daratumumab Is an Effective and Safe Salvage Therapy in Relapsed/Refractory Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation

Evgeny Klyuchnikov, MD, Ute-Marie von Pein, MD, Francis A. Ayuk, MD, Maximilian Christopeit, MD, Raissa Adjalle, MD, Andre van Randenborgh, MD, Christine Wolschke, MD, Nicolaus Kröger

Blood (2016) 128 (22): 3437.

https://doi.org/10.1182/blood.V128.22.3437.3437

Published: 2016

Journal Articles

Nilotinib As Second-Line Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase: Thailand Experience

Kanchana Chansung, MD, Chittima Sirijerachai, MD, Arnuparp Lekhakula, MD MS, Pongtep Viboonjuntra, MDPhD, Pimjai Niparuck, MD, Teeraya Pauvilai, MD, Tontanai Numbenjapon, MD, Udomsak Bunworasate, MD, Weerasak Nawarawong, MD, Adisak Tantiworawit, MD, Tawatchai Suwanban, MD, Saengsuree Jootar

Blood (2016) 128 (22): 5448.

https://doi.org/10.1182/blood.V128.22.5448.5448

Published: 2016

Journal Articles

Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study

Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Peter Tan, James D'Rozario, John Taper, MBBS FRACP FRCPA, Anthony Richard Powell, FRACP, MBBS, Ian Irving, Matthew P.F. Wright, MBBS, FRCPA, FRACP, Susan Branford, PhD FFSc (RCPA), David T. Yeung, BSc, MBBS, FRACP, FRCPA, Luke Anderson, Othon L Gervasio, Timothy P. Hughes, MD

Blood (2016) 128 (22): 5447.

https://doi.org/10.1182/blood.V128.22.5447.5447

Published: 2016

Journal Articles

Real-World Safety Experience for Short-Acting Recombinant Human Granulocyte Colony-Stimulating Factor

Camille N Abboud, Nicole Lang, Andreas Lammerich, Anton Buchner, Patrick Liu, Udo Mueller, Ashutosh Pathak

Blood (2016) 128 (22): 2504.

https://doi.org/10.1182/blood.V128.22.2504.2504

Published: 2016

Journal Articles

Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia

Antonio G. Piga, MD, Immacolata Tartaglione, MD, Rita Gamberini, MD, Ersi Voskaridou, MD, Angela Melpignano, MD, Paolo Ricchi, MD, Vincenzo Caruso, MD, Antonello Pietrangelo, MD, Xiaosha Zhang, Dawn M. Wilson, Ashley Leneus, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2016) 128 (22): 851.

https://doi.org/10.1182/blood.V128.22.851.851

Published: 2016

Journal Articles

Generic Imatinib in Chronic Myeloid Leukemia: Survival of the Cheapest

Danthala Madhav

Blood (2016) 128 (22): 630.

https://doi.org/10.1182/blood.V128.22.630.630

Published: 2016

NARROW

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Real-World Effectiveness and Safety of Eltrombopag in Patients with Aplastic Anemia: A Chinese Nationwide Survey

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Impact of Early Switching to Nilotinib As Second Line TKI in Patients with Chronic Myeloid Leukemia Who Were Intolerant to, Suboptimal to and Failed Imatinib: The Thai Multi-Centered Study

Erythrocyte Deformability As a Potential Biomarker for Chronic Fatigue Syndrome

Relationship between Non-Prescribed Drug Use and Employment Status of Patients with Sickle Cell Disease

Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort

Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Variables Associated with Patient-Reported Symptoms in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors

Pilot Study of Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia with Deep Molecular Response (EDI-PIO) — Evaluation of Pioglitazone in Treatment-Free Remission

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Daratumumab Is an Effective and Safe Salvage Therapy in Relapsed/Refractory Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation

Nilotinib As Second-Line Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase: Thailand Experience

Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study

Real-World Safety Experience for Short-Acting Recombinant Human Granulocyte Colony-Stimulating Factor

Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia

Generic Imatinib in Chronic Myeloid Leukemia: Survival of the Cheapest

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only